Score Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Score Pharma is a private, pre-revenue biotechnology company developing next-generation, ADCC-enhanced antibody therapeutics for oncology. Its core innovation is a proprietary process technology designed to modify existing, clinically-validated antibodies to increase their potency and improve patient response, aiming to radically de-risk and shorten the traditional drug development timeline. The company initially targets HER2-positive breast cancer, melanoma, renal cell carcinoma, and colorectal cancer. Operating with a virtual model based in Alabama, it relies on strategic partnerships and external resources to advance its pipeline.

Oncology

Technology Platform

Proprietary process technology for enhancing Antibody-Dependent Cellular Cytotoxicity (ADCC) by modifying the glycosylation of existing therapeutic antibodies.

Opportunities

The large and established market for antibody therapies in oncology provides a clear foundation for developing enhanced 'biobetter' versions with improved efficacy.

The proprietary process technology offers a potentially derisked and accelerated development path by building upon clinically validated molecules, which is attractive for strategic partnerships and funding.

Risk Factors

The company faces significant technical risk in translating its platform into clinically superior therapies, and intense competition in the antibody enhancement space.

Its virtual, partnership-dependent model creates execution risk, as success is contingent on securing alliances with antibody holders for development and commercialization.

Competitive Landscape

Score Pharma operates in the competitive field of antibody Fc engineering and biobetter development, competing with companies like Kyowa Kirin (POTELLIGENT®), BioWa (POTELLIGENT® licensed), and numerous biotechs focused on glycoengineering. It also competes for partnership attention with larger biopharma companies that have internal antibody development platforms.

More companies in Biologics / Biosimilars →More companies in United States →